Long-term Developmental Neuropsychiatric Comorbidities of Pediatric Exposure to DFP Status Epilepticus
Abstract number :
2.472
Submission category :
7. Anti-seizure Medications / 7A. Animal Studies
Year :
2022
Submission ID :
2232875
Source :
www.aesnet.org
Presentation date :
12/4/2022 12:00:00 PM
Published date :
Nov 22, 2022, 05:28 AM
Authors :
Michael Neff, B.S. – Texas A&M School of Medicine; Tanveer Singh, P.hD – Texas A&M School of Medicine; Xin Wu, M.D. – Texas A&M School of Medicine; D. Samba Reddy, P.hD – Texas A&M School of Medicine
This is a Late Breaking abstract
Rationale: Children are more susceptible to seizures and the neurotoxic effects of organophosphates (OP) and nerve agents. Both children and neonates are at risk for exposure to OP pesticides, with whom developmental risks are a critical concern. Pediatric OP exposure can lead to acute seizures and neuropsychiatric sequela including developmental disabilities and cognitive impairments. However, there are few epilepsy models that use pediatric OP exposure for studying neuron developmental consequences and interventions.
Methods: In this study, we investigated the long-term developmental impact of neonatal exposure to the OP compound diisopropyl fluorophosphate (DFP) that induced status epilepticus (SE) in pediatric rats. P28 rat pups were exposed to DFP and were treated with midazolam and an atropine regimen for seizure control and survival. Ten months after exposure, animals were evaluated in an array of mood and behavior tests such as open-field, plus-maze, novel object recognition, and water-maze memory testing.
Results: At 10 months post-SE, animals displayed significant deficits in mood and anxiety behavior compared to age-matched controls. Animals displayed marked aggressive traits, deficits in object recognition memory, and decreased ability in spatial learning and memory. Neurosteroid treatment resulted in an improved index of mood and cognition as compared to the control group.
Conclusions: This pediatric model replicates many features of children with OP-SE. This suggests its viability for therapeutic screenings, such as testing neuroprotectant interventions.
Funding: This work was supported by NIH Grant U01-NS117209.
Anti-seizure Medications